On April 15, 2019 Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported it has received a $1,000,000 payment from Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) of South Korea (Press release, Can-Fite BioPharma, APR 15, 2019, View Source [SID1234535131]). CKD has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and non-alcoholic steatohepatitis (NASH) in a deal totaling $6,000,000 in upfront and milestone payments, plus a transfer price for delivering finished products to CKD. The current $1,000,000 payment is an upfront payment for the expansion of CKD’s existing agreement with Can-Fite to include the rights to distribute Namodenoson for the treatment of NASH in South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we advance our pipeline of drugs, we are pleased to work with our expanding network of global distribution partners for Namodenoson and Piclidenoson," stated Can-Fite CEO Pnina Fishman.